Antibodies Targeting the ErbB2/ErbB3/IGF-1R Complex as Therapeutics for ErbB2 Positive Breast Cancer

靶向 ErbB2/ErbB3/IGF-1R 复合物的抗体作为 ErbB2 阳性乳腺癌的治疗药物

• 批准号: 270041
• 负责人: Liu Jianghai
• 金额: $ 9.83万
• 依托单位: University of Saskatchewan
• 依托单位国家: 加拿大
• 项目类别: Fellowship Programs
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-10-01 至 2015-10-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=270041&lang=en
• 关键词: Antibody Therapy For Breast Cancer; Erbb Receptors; Igf-1 Receptor; Phage Display

The use of the antibody trastuzumab to inhibit human epidermal growth factor receptor 2 (erbB2), which is present on specific types of breast cancer, is a paradigm shift in cancer therapy, as it provides a more specific and less toxic approach to treat br

使用抗体曲妥珠单抗抑制人表皮生长因子受体 2 (erbB2)（存在于特定类型的乳腺癌中）是癌症治疗的范式转变，因为它提供了一种更特异且毒性更小的方法来治疗乳腺癌。